June 2014 Volume 10, Issue 6

Volume 10, Issue 6 | June 2014

June 2014

In this Issue

Research & Development

Drug Discovery News Placeholder Image

Going global against Alzheimer’s

World Dementia Council sets strategies to reach the goal of treatment by 2025
Drug Discovery News Placeholder Image

Serum stable

Novozymes Biopharma will offer a drug-albumin conjugation platform in collaboration with ThioLogics
Drug Discovery News Placeholder Image

Getting more ‘MIF’ed

Debiopharm and Yale broaden collaboration on MIF inhibitors for autoimmune and inflammatory diseases
Drug Discovery News Placeholder Image

New biochip mimics liver

Technology promises simplified toxicity testing of drug candidates

Special Reports

Drug Discovery News Placeholder Image

Special Report: Cancer in the clinic - Are we all fighting for the same endgame?

A little over a year ago, we published a special report on the challenges facing new oncology drugs as they moved through the clinical trial process. This time, Randall C Willis looks further into this challenge by examining the clinical trial process itself

Q&A

Drug Discovery News Placeholder Image

Carbohydrate-based answers for diabetes, hypoxic tissue and cell death

DDNews spends some time talking to Dr. David Platt of Boston Therapeutics Inc. about carbohydrate chemistry and his company's work, and what it all means to some key areas of concern in drug discovery and healthcare

Editor's Focus

Drug Discovery News Placeholder Image

The word on ‘The Street’ is: Shopping

DDNews' chief editor muses on merger and acquisition trends in pharma and biotech and some films about Wall Street, and ponders whether the big-money M&As are worth it overall (for the industry and the patients)

Commentary

Drug Discovery News Placeholder Image

Red tape rising

We’ve reached the stage where the pursuit of funding is overtaking the pursuit of doing science, says columnist Peter T. Kissinger, and that isn't good for anyone, nor is the idea of envisioning a world where everyone who wants grants gets them
Drug Discovery News Placeholder Image

Guest commentary: The clinical trial landscape and its data collection challenges

Clinical trials are one of the most important components of the drug development process, but they are also one of the most costly, and much of that expense (both money and time) is due to data collection

Preclinical

Drug Discovery News Placeholder Image

See how they run

Mice with MS-like virus recover after human stem cell injections, offering hope for human cure
Drug Discovery News Placeholder Image

New antiviral drug targets measles outbreaks

If it works in humans, it could protect infected people from getting sick and keep them from spreading the virus
Drug Discovery News Placeholder Image

Disease-modifying treatment for COPD

Domainex program shows promise for treatment of not just COPD but possibly other inflammatory diseases
Drug Discovery News Placeholder Image

Facing down Factor VIII intolerance

Apitope moves potential hemophilia A peptide therapy into preclinical development

Business & Government Policy

Drug Discovery News Placeholder Image

Pfizer loses bid for AstraZeneca

Final offer of $117 billion insufficient to allay concerns about Pfizer’s plans and woo AstraZeneca to negotiating table
Drug Discovery News Placeholder Image

Valeant vies for Allergan

In light of Allergan’s rejection of its merger proposal, Valeant ups the ante
Drug Discovery News Placeholder Image

Takeda, Eli Lilly found liable by jury in Actos claims

Verdict calls upon the companies to pay $9 billion in damages over bladder cancer possibly related to Actos use
Drug Discovery News Placeholder Image

GSK, Novartis ink transformational agreement

Transaction expected to result in a leading OTC business with $10 billion in sales
Drug Discovery News Placeholder Image

Allergy shot alternative

Two new sublingual drugs combat common allergies

Clinical Trials

Drug Discovery News Placeholder Image

Taking a swipe at resistant infections

Cubist moves treatment for antibiotic-resistant infections beyond Phase 3
Drug Discovery News Placeholder Image

Shire to acquire Lumena in pipeline expansion

Acquisition strengthens Irish company’s rare disease pipeline and profitable GI business
Drug Discovery News Placeholder Image

Going for leadership in cellular therapy

NeoStem acquires California Stem Cell and moves forward with Phase 3 trial for melanoma
Drug Discovery News Placeholder Image

Aegerion looks to bring lomitapide to Japan

Phase 3 trial focuses on treatment of homozygous familial hypercholesterolemia
Drug Discovery News Placeholder Image

Hope for prostate cancer and BPH

Nymox reports that prostate cancer treatment does not affect testosterone levels

Diagnostics

Drug Discovery News Placeholder Image

Idera and Abbott seek new companion

Abbott will develop a companion diagnostic for Idera’s IMO-8400 for use in genetically defined forms of B-cell lymphoma
Drug Discovery News Placeholder Image

Going international

Foundation Medicine announces key developments in international commercialization efforts
Drug Discovery News Placeholder Image

Curtailing a ‘diagnostic odyssey’

Indi’s Series B round will help commercialize Xpresys Lung, a diagnostic for identifying benign lung nodules
Drug Discovery News Placeholder Image

On point

DNA Electronics secures funding to develop Genalysis point-of-care genomic diagnostics product line

Discovery

Drug Discovery News Placeholder Image

Playbook for a pathogen

Researchers sequence H99 strain of Cryptococcus neoformans, a potentially deadly human pathogen
Drug Discovery News Placeholder Image

Calibr receives Gates Foundation grant

Goal is to lead collaborations to develop an Integrated Drug Discovery Platform for diseases of the developing world
Drug Discovery News Placeholder Image

A natural fit for natural products?

California’s ChromaDex pairs with Brazil’s LNBio for joint research agreement
Drug Discovery News Placeholder Image

Scripps launches new drug discovery initiative

Aim is to translate early-stage biomedical research into clinical candidates
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue